October 5, 2017 / 11:15 AM / 2 months ago

BRIEF-Neurocrine announces FDA approval of 80 mg Ingrezza

Oct 5 (Reuters) - Neurocrine Biosciences Inc:

* Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD)

* Says ‍80 mg capsule of Ingrezza will be available for patients within two weeks through a select pharmacy network​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below